UBS Group
AUGX

UBS Group’s Augmedix, Inc. Common Stock AUGX Stock Holding History

UBS Group’s Portfolio AUGX Stock Details AUGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-17,547
Closed -$41.2K – 10758
2024
Q3 		$41.2K Sell
17,547
-23,867
-58% -$48.2K ﹤0.01% 6939
2024
Q2 		$36.4K Buy
41,414
+22,314
+117% +$46K ﹤0.01% 6929
2024
Q1 		$78.1K Buy
+19,100
New +$85.5K ﹤0.01% 6321
2023
Q2 		– Sell
-6,171
Closed -$10.7K – 9906
2023
Q1 		$10.7K Sell
6,171
-421
-6% -$687 ﹤0.01% 7553
2022
Q4 		$10.3K Buy
6,592
+386
+6% +$492 ﹤0.01% 8540
2022
Q3 		$9K Sell
6,206
-540
-8% -$926 ﹤0.01% 8618
2022
Q2 		$12K Buy
6,746
+2,808
+71% +$6.5K ﹤0.01% 7698
2022
Q1 		$12K Sell
3,938
-1,892
-32% -$5.13K ﹤0.01% 8213
2021
Q4 		$18K Buy
+5,830
New +$21.1K ﹤0.01% 7999

UBS Group's AUGX Position: Q4 2024 in Review

UBS Group sold out of Augmedix, Inc. Common Stock (AUGX) in Q4 2024, closing a stake of 17,547 shares — an estimated $41.2K sold.

UBS Group first reported a position in AUGX in Q4 2021 and held it in 9 quarters. The position peaked at $78.1K in Q1 2024. 0 funds tracked by Wall St. Rank hold AUGX as of Q4 2024.

  • UBS Group reported no remaining Augmedix, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • UBS Group sold 17,547 Augmedix, Inc. Common Stock shares in Q4 2024, an estimated $41.2K.
  • UBS Group first reported a position in Augmedix, Inc. Common Stock in Q4 2021 and held it in 9 quarters.
  • UBS Group's Augmedix, Inc. Common Stock position peaked at $78.1K in Q1 2024.
  • 0 funds tracked by Wall St. Rank held Augmedix, Inc. Common Stock as of Q4 2024.

Based on UBS Group's 13F filing for Q4 2024, filed 14 Feb 2025.